Table 3.
Renal clearance of biomarkers after empagliflozin/dapagliflozin treatment
| At baseline | After placebo | After verum | ||||
|---|---|---|---|---|---|---|
| p-value [adj. p-value] vs. baseline (n) | p-value [adj. p-value] vs. baseline (n) | p-value [adj. p-value] vs. placebo (n) | ||||
| Empagliflozin | ||||||
| Homoarginine | 1.147 ± 1.243 | 1.058 ± 0.920 | 0.922 [0.965] (68) | 1.057 ± 0.955 | 0.564 [0.705] (70) | 0.224 [0.388] (69) |
| Arginine | 0.303 ± 0.232 | 0.272 ± 0.198 | 0.148 [0.290] (68) | 0.292 ± 0.186 | 0.998 [0.998] (69) | 0.174 [0.326] (70) |
| ADMA | 84.07 ± 26.00 | 85.74 ± 28.17 | 0.786 [0.863] (70) | 71.01 ± 25.09 | < 0.001 [0.001] (71) | 0.001 [0.005] (70) |
| SDMA | 81.51 ± 25.14 | 81.73 ± 24.18 | 0.956 [0.978] (70) | 74.08 ± 25.09 | 0.004 [0.015] (71) | 0.012 [0.039] (70) |
| Creatinine | 116.83 ± 37.52 | 113.75 ± 33.31 | 0.129 [0.264] (70) | 101.16 ± 31.23 | < 0.001 [< 0.001] (71) | 0.002 [0.008] (70) |
| Dapagliflozin | ||||||
| Homoarginine | 1.092 ± 1.708 | 1.167 ± 1.547 | 0.636 [0.774] (57) | 1.077 ± 0.765 | 0.023 [0.090] (57) | 0.431 [0.604] (55) |
| Arginine | 0.258 ± 0.175 | 0.306 ± 0.222 | 0.029 [0.093] (57) | 0.320 ± 0.206 | 0.016 [0.090] (58) | 0.396 [0.604] (56) |
| ADMA | 75.24 ± 25.75 | 86.12 ± 33.67 | 0.009 [0.058] (57) | 79.04 ± 32.34 | 0.498 [0.659] (58) | 0.101 [0.216] (56) |
| SDMA | 83.09 ± 31.11 | 90.68 ± 32.49 | 0.049 [0.138] (57) | 79.89 ± 31.21 | 0.432 [0.604] (58) | 0.019 [0.090] (56) |
| Creatinine | 114.03 ± 41.05 | 119.36 ± 41.44 | 0.319 [0.552] (57) | 106.38 ± 40.49 | 0.097 [0.216] (58) | 0.024 [0.090] (56) |
Data are given in mL/min as mean ± SD, calculated as (curine * Vurine) / (cplasma * 1440 min); p-values calculated by Wilcoxon signed-rank test, adj. p-values computed based on the procedure of Benjamini and Hochberg; p-values refer to the absolute changes in biomarker ClR